<DOC>
	<DOCNO>NCT02027337</DOCNO>
	<brief_summary>We investigate parameter hemocoagulation lipoperoxidation woman use combined oral contraceptive antiandrogenic activity ( contain drospirenone 20 30 mcg ethinylestradiol ; cyproterone acetate ) ; correction change antioxidant</brief_summary>
	<brief_title>Hemocoagulation Lipoperoxidation Women Using Combined Oral Contraceptives , Correction Antioxidants</brief_title>
	<detailed_description>It well know hormonal contraceptive use increase risk thrombosis . We conduct parameter hemostasis woman use combined oral contraceptive antiandrogenic activity contraception treatment . Considering relationship lipoperoxidation platelet hemostasis expect limitation lipoperoxidation antioxidant restrict hypercoagulation decrease risk thrombosis . The purpose study decrease thrombosis risk woman use combined oral contraceptive contain 20 mcg ethinylestradiol/3 mg drospirenone , 30 mcg ethinylestradiol/3 mg drospirenone , 35 mcg ethinylestradiol/2mg cyproterone acetate . Half woman arm ( group ) receive combine oral contraceptive ( COC ) , woman receive combine oral contraceptive antioxidant complex Selmevit . The blood test conduct 19-21 day menstrual cycle COC use ( control group ) 19-21 day COC use 1 , 3 , 6 12 cycle . Also investigate subjective tolerability , therapeutic effect , menstrual cycle control adverse effect COCs woman antioxidant complex Selmevit</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Cyproterone acetate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Women age 1835 year Absence contraindication COC use Informed voluntary consent examination Age young 18 old 35 year Refusal failure comply study protocol Drug alcohol dependence Psychiatric diseases Severe somatic allergic disease Pregnancy Malignancies Taking drug affect haemostasis , include hormonal contraceptive 6 month study begin Cases thrombosis among firstline relative family history Contraindications COC use Eligibility Criteria hormonal contraception ( WHO , 2012 )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>combine oral contraceptive</keyword>
	<keyword>drospirenone</keyword>
	<keyword>cyproterone</keyword>
	<keyword>hemostasis</keyword>
	<keyword>antioxidant</keyword>
</DOC>